Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 2Seventy Bio Inc TSVT

Healthcare Biotechnology
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol... see more

Recent & Breaking News (NDAQ:TSVT)

Levi & Korsinsky Investigates Possible Securities Fraud Violations by 2seventy bio, Inc. (TSVT)

Accesswire September 27, 2024

TSVT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of 2seventy bio, Inc. Shareholders Who Lost Money

Accesswire September 27, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT

PR Newswire September 27, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Reach Out

Accesswire September 27, 2024

TSVT ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by 2seventy bio, Inc.

Accesswire September 26, 2024

Bronstein, Gewirtz & Grossman, LLC Is Investigating 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Connect

Accesswire September 26, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT

Accesswire September 26, 2024

2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance

Business Wire September 25, 2024

2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference

Business Wire August 29, 2024

2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress

Business Wire August 7, 2024

2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024

Business Wire August 5, 2024

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

Business Wire June 26, 2024

2seventy bio to Participate in Upcoming Investor Conferences

Business Wire May 23, 2024

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

Business Wire May 8, 2024

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

Business Wire May 3, 2024

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Business Wire April 5, 2024

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

Business Wire April 1, 2024

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

Business Wire March 20, 2024

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

Business Wire March 15, 2024

2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress

Business Wire March 5, 2024